BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 8, 2002
View Archived Issues
Celgene Changing Course On Thalomid In Multiple Myeloma
Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today)
Read More
Cubist Plans Cidecin NDA Filing This Year For Treating Infections
Read More
Besides Biting Fly, Parasitical Worm, River Blindness Needs Wolbachia Bacterial Infectivity
Read More
PDUFA Negotiations Likely To Lead To Increased Filing Fees
Read More
Other News To Note
Read More
Medicines Company Licenses Phase III Drug From AstraZeneca
Read More
U.S. Patent Disclosures
Read More